<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34820130</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2050-313X</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>SAGE open medical case reports</Title><ISOAbbreviation>SAGE Open Med Case Rep</ISOAbbreviation></Journal><ArticleTitle>Severe COVID-19 and long COVID in a 31-year-old woman with incontinentia pigmenti: A case report.</ArticleTitle><Pagination><StartPage>2050313X211059295</StartPage><MedlinePgn>2050313X211059295</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2050313X211059295</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/2050313X211059295</ELocationID><Abstract><AbstractText>Incontinentia pigmenti is a rare genetic disease affecting the skin, microvasculature, and central nervous system, in which a hyperactive inflammatory response is observed. Due to the inflammatory phase of COVID-19 and associated cytokine storm, infection with SARS-CoV-2 in individuals with incontinentia pigmenti is a concern. Furthermore, type I interferon autoantibodies are found in life-threatening COVID-19 pneumonia and in 25% of individuals with incontinentia pigmenti. The present case report describes a 31-year-old Caucasian woman with incontinentia pigmenti and severe COVID-19. She was hospitalized for oxygen therapy, intravenous antibiotics, and corticosteroids. Eight&#x2009;months later, she is still symptomatic. To our knowledge, she is the first reported case of long COVID in incontinentia pigmenti. Increased autoimmunity may be implicated in both incontinentia pigmenti and long COVID. Pending evidence-based guidelines, COVID-protective measures including vaccination should be recommended to all patients with incontinentia pigmenti. Specific interferon therapy may be considered along with usual COVID treatment.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rheault</LastName><ForeName>Sylvie</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0227-1624</Identifier><AffiliationInfo><Affiliation>Centre de recherche de l'Institut universitaire de g&#xe9;riatrie de Montr&#xe9;al/Universit&#xe9; de Montr&#xe9;al, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>SAGE Open Med Case Rep</MedlineTA><NlmUniqueID>101638686</NlmUniqueID><ISSNLinking>2050-313X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Infectious disease</Keyword><Keyword MajorTopicYN="N">NEMO</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">TNF-&#x3b1;</Keyword><Keyword MajorTopicYN="N">apoptosis</Keyword><Keyword MajorTopicYN="N">autoantibodies</Keyword><Keyword MajorTopicYN="N">incontinentia pigmenti</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">type I interferon autoantibodies</Keyword></KeywordList><CoiStatement>Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34820130</ArticleId><ArticleId IdType="pmc">PMC8606980</ArticleId><ArticleId IdType="doi">10.1177/2050313X211059295</ArticleId><ArticleId IdType="pii">10.1177_2050313X211059295</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bruckner AL. Incontinentia pigmenti: a window to the role of NF-kappaB function. Semin Cutan Med Surg 2004; 23(2): 116&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">15295921</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebban H, Courtois G. NF-kappaB and inflammation in genetic disease. Biochem Pharmacol 2006; 72: 1153&#x2013;1160.</Citation><ArticleIdList><ArticleId IdType="pubmed">16965764</ArticleId></ArticleIdList></Reference><Reference><Citation>Honig PJ, Miller ME. Incontinentia pigmenti &#x2013; a possible immunologic disorder. J Pediatr 1972; 80(2): 334&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">5008835</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohnishi H, Kishimoto Y, Taguchi T, et al.. Immunodeficiency in two female patients with incontinentia pigmenti with heterozygous NEMO mutation diagnosed by LPS unresponsiveness. J Clin Immunol 2017; 37(6): 529&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pubmed">28702714</ArticleId></ArticleIdList></Reference><Reference><Citation>Fusco F, Pescatore A, Conte MI, et al.. EDA-ID and IP, two faces of the same coin: how the same IKBKG/NEMO mutation affecting the NF-&#x3ba;B pathway can cause immunodeficiency and/or inflammation. Int Rev Immunol 2015; 34: 445&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pubmed">26269396</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Valle DM, Kim-Schulze S, Huang HH, et al.. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med 2020; 26(10): 1636&#x2013;1643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7869028</ArticleId><ArticleId IdType="pubmed">32839624</ArticleId></ArticleIdList></Reference><Reference><Citation>W&#xf6;lfel R, Corman VM, Guggemos W, et al.. Virological assessment of hospitalized patients with COVID-2019. Nature 2020; 581: 465&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pubmed">32235945</ArticleId></ArticleIdList></Reference><Reference><Citation>Meffre E, Iwasaki A. Interferon deficiency can lead to severe COVID. Nature 2020; 587(7834): 374&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">33139913</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Rosen LB, Zhang Q, et al.. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 2020; 370: eabd4585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Gervais A, Le Voyer T, et al.. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol 2021; 6: eabl4340.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8521484</ArticleId><ArticleId IdType="pubmed">34413139</ArticleId></ArticleIdList></Reference><Reference><Citation>American Academy of Pediatrics Committee on Fetus and Newborn, American College of Obstetricians and Gynecologists Committee on Obstetric Practice. The Apgar score. Pediatrics 2015; 136: 819&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasreddine ZS, Phillips NA, B&#xe9;dirian V, et al.. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53(4): 695&#x2013;699.</Citation><ArticleIdList><ArticleId IdType="pubmed">15817019</ArticleId></ArticleIdList></Reference><Reference><Citation>Nepotchatykh E, Elremaly W, Caraus I, et al.. Profile of circulating microRNAs in myalgic encephalomyelitis and their relation to symptom severity, and disease pathophysiology. Sci Rep 2020; 10: 19620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665057</ArticleId><ArticleId IdType="pubmed">33184353</ArticleId></ArticleIdList></Reference><Reference><Citation>Tremblay K, Rousseau S, Zawati MH, et al.. The Biobanque qu&#xe9;b&#xe9;coise de la COVID-19 (BQC19)-A cohort to prospectively study the clinical and biological determinants of COVID-19 clinical trajectories. PLoS ONE 2021; 16(5): e0245031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8133500</ArticleId><ArticleId IdType="pubmed">34010280</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Guo Y, Ping Y, et al.. Neonatal incontinentia pigmenti: six cases and a literature review. Exp Ther Med 2014; 8(6): 1797&#x2013;1806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4218682</ArticleId><ArticleId IdType="pubmed">25371735</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, L&#xe9;vy R, Henriquez S, et al.. Interferon-&#x3b2; Therapy in a Patient with Incontinentia Pigmenti and Autoantibodies against Type I IFNs Infected with SARS-CoV-2. J Clin Immunol 2021; 41(5): 931&#x2013;933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7990897</ArticleId><ArticleId IdType="pubmed">33763778</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al.. Attributes and predictors of long COVID. Nat Med 2021; 27: 626&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, et al.. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397: 220&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>